SCHEMBL23945776

SCHEMBL23945776

CCCCCCC(CCC)C(=O)N1CCC2(CC1)CN(CCCC(CC)CCCC)C2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.37
TSHR P16473 1/20 0.37
USP2 O75604 1/20 0.37
ALDH1A1 P00352 1/20 0.34
CA2 P00918 4/20 0.33
S1PR1 P21453 2/20 0.33
S1PR3 Q99500 2/20 0.33
S1PR5 Q9H228 2/20 0.33
S1PR4 O95977 1/20 0.33
EPHX2 P34913 1/20 0.32
CHRM2 P08172 1/20 0.32
HTR1A P08908 1/20 0.32
ADRA2A P08913 1/20 0.32
ADORA3 P0DMS8 1/20 0.32
CHRM1 P11229 1/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32
OPRM1 P35372 1/20 0.32
DRD3 P35462 1/20 0.32
SLC6A3 Q01959 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25884460 0.98 LMNA (0.37) LMNATSHRUSP2ALDH1A1CA2
SCHEMBL26405356 0.98 USP2 (0.38) LMNATSHRUSP2ALDH1A1CA2
SCHEMBL25923944 0.93 TSHR (0.35) LMNATSHRUSP2ALDH1A1CA2
SCHEMBL25707635 0.93 LMNA (0.37) LMNATSHRUSP2ALDH1A1CA2
SCHEMBL25707293 0.92 TSHR (0.39) LMNATSHRUSP2ALDH1A1CA2
SCHEMBL26408578 0.89 USP2 (0.41) LMNATSHRUSP2ALDH1A1CA2
SCHEMBL24673675 0.89 LMNA (0.38) LMNATSHRUSP2ALDH1A1S1PR1
SCHEMBL25122691 0.89 TSHR (0.37) LMNATSHRUSP2ALDH1A1CA2
SCHEMBL25927357 0.89 TSHR (0.37) LMNATSHRUSP2ALDH1A1CA2
SCHEMBL23807008 0.87 CYP2C19 (0.37) LMNATSHRUSP2ALDH1A1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 LMNA 1656/4885TSHR 3319/4885USP2 141/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 LMNA 1656/4885TSHR 3319/4885USP2 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.